山东新华制药股份(00719.HK)：获得缬沙坦胶囊药品注册证书

Group 1 - The core point of the article is that Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration certificate of Valsartan capsules, which are used to treat mild to moderate primary hypertension [1] Group 2 - The approval signifies a regulatory milestone for the company, potentially enhancing its product portfolio in the cardiovascular medication market [1] - Valsartan is a well-known medication in the treatment of hypertension, indicating a strategic move by the company to address a significant health issue [1] - The introduction of Valsartan capsules may lead to increased revenue opportunities for the company in the pharmaceutical sector [1]